

Variant: NM_007294.4(BRCA1):c.68_69del (p.Glu23fs)

Version: 2.0

CA003783 [↗](#)

17662 (ClinVar) [↗](#)

Gene: BRCA1 ([HGNC:672](#))

Condition: BRCA1-related cancer predisposition ([MONDO:0700268](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: 8cc9bd83-9b2d-4a38-ba40-c2010955350d

Approved on: 2024-06-12

Published on: 2024-06-12

HGVS expressions

NM_007294.4:c.68_69del

NM_007294.4(BRCA1):c.68_69del (p.Glu23fs)
NC_000017.11:g.43124030_43124031del
CM000679.2:g.43124030_43124031del
NC_000017.10:g.41276047_41276048del
CM000679.1:g.41276047_41276048del
NC_000017.9:g.38529573_38529574del
NG_005905.2:g.93955_93956del
ENST00000354071.8:n.132_133del
ENST00000461574.2:c.68_69del
ENST00000470026.6:c.68_69del
ENST00000473961.6:c.68_69del
ENST00000476777.6:c.68_69del
ENST00000477152.6:c.68_69del
ENST00000478531.6:c.68_69del
ENST00000489037.2:c.68_69del
ENST00000493919.6:c.-20_-19del
ENST00000494123.6:c.68_69del
ENST00000497488.2:c.-219+1242_-219+1243del
ENST00000618469.2:c.68_69del
ENST00000634433.2:c.68_69del
ENST00000644379.2:c.68_69del
ENST00000644555.2:c.-219_-218del
ENST00000652672.2:c.-193_-192del
ENST00000484087.6:c.68_69del
ENST00000700182.1:c.68_69del
ENST00000700183.1:c.68_69del
ENST00000700184.1:n.311_312del
ENST00000700185.1:n.187_188del
ENST00000700186.1:n.187_188del
ENST00000357654.9:c.68_69del
ENST00000471181.7:c.68_69del
ENST00000642945.1:c.68_69del
ENST00000644555.1:c.-219_-218del
ENST00000652672.1:c.-193_-192del
ENST00000352993.7:c.68_69del
ENST00000354071.7:c.68_69del

ENST00000357654.7:c.68_69del
ENST00000461221.5:c.68_69del
ENST00000461798.5:c.68_69del
ENST00000468300.5:c.68_69del
ENST00000470026.5:c.68_69del
ENST00000471181.6:c.68_69del
ENST00000476777.5:c.68_69del
ENST00000477152.5:c.68_69del
ENST00000478531.5:c.68_69del
ENST00000489037.1:c.68_69del
ENST00000491747.6:c.68_69del
ENST00000492859.5:c.68_69del
ENST00000493795.5:c.-20_-19del
ENST00000493919.5:c.-20_-19del
ENST00000494123.5:c.68_69del
ENST00000497488.1:c.-219+1242_-219+1243del
ENST00000586385.5:c.4+1153_4+1154del
ENST00000591534.5:c.-44+1242_-44+1243del
ENST00000591849.5:c.-99+1242_-99+1243del
ENST00000618469.1:c.68_69del
ENST00000634433.1:c.68_69del
NM_007294.3:c.68_69del
NM_007297.3:c.-20_-19del
NM_007298.3:c.68_69del
NM_007299.3:c.68_69del
NM_007300.3:c.68_69del
NR_027676.1:n.229_230del
NM_007297.4:c.-20_-19del
NM_007299.4:c.68_69del
NM_007300.4:c.68_69del
NR_027676.2:n.270_271del

Pathogenic

Met criteria codes **3**

PS3 PM5_Strong PVS1

Not Met criteria codes **3**

BA1 PM2 BS1

Evidence Links **0**

Expert Panel

[ENIGMA BRCA1 and BRCA2 VCEP](#)

Criteria Specification Information

[Criteria Specification:](#) *ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for BRCA1 Version 1.0.0*

[Criteria Specification Approval History](#)

[Criteria Specifications for this VCEP](#)







Evidence submitted by expert panel

ENIGMA BRCA1 and BRCA2 VCEP






The c.68_69del variant in BRCA1 is a deletion of two nucleotides, predicted to encode a frameshift with consequent premature termination of the protein at codon 17 of the frameshift, or amino acid 39 (p.Glu23ValfsTer17). This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting

(PM2_Supporting, BS1, and BA1 are not met). Frameshift variant predicted to cause a premature stop codon in biologically-relevant-exon 3 leading to nonsense mediated decay (PVS1 met). The ENIGMA BRCA1/2 VCEP considered multiple lines of functional and clinical evidence to define exon-specific weights for PTC in BRCA1, and results indicate that strong evidence towards pathogenicity may be applied for a PTC variant in BRCA1 exon 3 (PM5_Strong (PTC)). Reported by one calibrated study to exhibit protein function similar to pathogenic control variants (PMID: 32546644) (PS3 met). In summary, this variant meets the criteria to be classified as a Pathogenic variant variant for BRCA1-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PVS1, PM5_Strong (PTC), PS3).

Met criteria codes

| | | |
|-------------------|---|--|
| PS3 |   | Reported by one calibrated study to exhibit protein function similar to pathogenic control variants (PMID: 32546644) (PS3 met). |
| PM5_Strong |   | The ENIGMA BRCA1/2 VCEP considered multiple lines of functional and clinical evidence to define exon-specific weights for PTC in BRCA1, and results indicate that strong evidence towards pathogenicity may be applied for a PTC variant in BRCA1 exon 3 (PM5_Strong (PTC)). |
| PVS1 |   | Frameshift variant predicted to cause a premature stop codon in biologically-relevant-exon 3 leading to nonsense mediated decay (PVS1 met). |

Not Met criteria codes

| | | |
|------------|---|---|
| BA1 |   | This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting (PM2_Supporting, BS1, and BA1 are not met). |
| PM2 |  | This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting (PM2_Supporting, BS1, and BA1 are not met). |
| BS1 |   | This variant is present in gnomAD v2.1 (exomes only, non-cancer subset) or gnomAD v3.1 (non-cancer subset) but is below the ENIGMA BRCA1/2 VCEP threshold >0.00002 for BS1_Supporting (PM2_Supporting, BS1, and BA1 are not met). |

Curation History [↗](#)



Showing 1 to 2 of 2 rows

| |
|------------|
| [Redacted] |
|------------|

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.